TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02402491
Drug: 24 months of P2Y12 receptor antagonist
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects will be received 24 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
Study: NCT02402491
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The maintenance dose of aspirin is 100 mg daily, to be taken indefinitely.
Study: NCT01731886
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally at a dose 25 mg daily on days 1-21 of each 28-day cycle.
Study: NCT01731886
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally at a dose of 40 mg daily on days 1, 8, 15, 22 of each cycle.
Study: NCT01731886
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects undergoing autologous peripheral blood stem cell transplant will receive melphalan 200 mg/m2 intravenously on days -2 and -1 or only on day -2.
Study: NCT01731886
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive G-CSF subcutaneously daily beginning on day 5 and until blood counts recover.
Study: NCT02289690
Drug: Veliparib
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules administered orally twice a day according to the dosing schedule.
Study: NCT02289690
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by intravenous infusion on Day 1 of each 21-day cycle over approximately 30 minutes at a target area under the curve (AUC) 5 mg/mL\*minute.
Study: NCT02289690
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by intravenous infusion on Days 1 to 3 of every 21-day cycle over approximately 60 minutes at 100 mg/m².
Study: NCT01731886
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesna will be provided with the cyclophosphamide.
Study: NCT00929058
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intra-arterial infusion during 6 minutes
Study: NCT01310361
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01020526
Drug: pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral capsule 75-450 mg/day
Study: NCT00056381
Drug: Anidulafungin
Normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00426179
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03573817
Drug: Revefenacin
Normalized name: Revefenacin
DrugBank: Revefenacin (DB11855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Revefenacin is administered via a nebulizer.
Study: NCT03573817
Drug: Formoterol
Normalized name: Formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered sequentially in both revefenacin and placebo arms using a nebulizer.
Study: NCT02013531
Drug: Brexpiprazole
Normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment (6 weeks) - Up to 3mg/day, once daily dose, tablets, orally
Study: NCT00094367
Drug: Abacavir/Lamivudine
Normalized name: ABACAVIR/LAMIVUDINE
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04273217
Drug: AV-1
Normalized name: AV-101
DrugBank: AV-101 (DB12878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, administered by IV infusion (volume: 250 mL)
Study: NCT03139240
Drug: Oxycodone 10mg oral
Normalized name: oxycodone 10 MG
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone 10mg oral given for pain control in addition to standard of care medications in women undergoing medical abortion
Study: NCT01396421
Drug: OPC-34712 [Brexpiprazole] High Dose
DrugBank: Brexpiprazole (DB09128)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Higher dose, tablet, once daily, for six weeks
Study: NCT01396421
Drug: Experimental: OPC-34712 [Brexpiprazole] Middle Dose
DrugBank: Brexpiprazole (DB09128)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Middle dose, tablet, once daily, for six weeks
Study: NCT01396421
Drug: Experimental: OPC-34712 [Brexpiprazole] Low Dose
DrugBank: Brexpiprazole (DB09128)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lower dose, tablet, once daily, for six weeks
Study: NCT00982631
Drug: Temsirolimus/PLD
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: This is a dose escalation study. Patients will start with temsirolimus iv once weekly. After 2 weeks, PLD therapy is added. From then on, PLD is repeated every 4 weeks. One cycle is 28 days. The DLT period is also defined within the first 28 days of combination therapy (thus the first 6 weeks of study participation). The first dose level (DL) is DL 1. Depending on toxicity, intermediate dose levels can be added. If no MTD is found in the sixth cohort, this dose level will be considered as the recommended dose (RD), being the optimal dose for both drugs in this combination. At the MTD dose level, the dose level will be expanded to a total of 12 patients.
Study: NCT04117893
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will start on duloxetine 30 mg per day for one week and then titrated up to duloxetine 60mg per day for 23 weeks.
Study: NCT03182751
Drug: Tranexamic Acid (TXA)
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenously via bolus dose of 1g over ten minutes and an additional 1g over the subsequent 8 hours
Study: NCT00957216
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300mg wafers; 2 wafers 4 times a day
Study: NCT00866645
Drug: Intramuscular Haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1ml：5mg/ampoul the recommended dose is 10 mg per day administered. Doses of 10 mg may be administered 5mg bid with an interval longer than 4 hours for 3 days.
Study: NCT00866645
Drug: Intramuscular Levosulpiride
DrugBank: Sulpiride (DB00391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2ml：50mg/ampoul the recommended dose is 100 mg per day administered. Doses of 100 mg may be administered 50mg bid with an interval longer than 4 hours for 3 days.
Study: NCT01843751
Drug: buprenorphine/naloxone
Normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine/naloxone (Suboxone) is considered a well-investigated, highly effective medication-assisted treatment for opiate dependence, but it may only be supervised through the few specialist treatment facilities in the state, or by physicians who have historically been less likely to offer this service. The effectiveness of community physician treatment supervision has not been tested for those in the criminal justice system.
Study: NCT00301171
Drug: Inhaled Fluticasone
Normalized name: fluticasone Inhalant Product
DrugBank: Fluticasone (DB13867)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00503113
Drug: Alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 70mg per oral (po) weekly
Study: NCT00475917
Drug: XL844
Normalized name: XL844
DrugBank: XL844 (DB05149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin capsules supplied as 5-mg, 25-mg, and 100-mg strengths; twice-weekly dosing.
Study: NCT00475917
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: once-weekly 30-minute IV infusion
Study: NCT03431337
Drug: Amoxicillin 875 mg
Normalized name: amoxicillin 875 MG
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doubling the dose of amoxicillin by adding amoxicillin 875 to each dose of the standard treatment of amoxicillin/clavulanate 875/125
Study: NCT01847222
Drug: Normal Saline Solution
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02999087
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of RT.
Study: NCT02999087
Drug: avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion of avelumab (10 mg/kg over 1 hour) once every 2 weeks. Avelumab will start on Day-8 together with cetuximab and subsequently every 2 weeks during the course of RT. Avelumab with be continued every 2 weeks for an additional 12 months following RT.
Study: NCT02999087
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/m² IV after hyperhydration and at a maximal rate of 1 mg/min, on days 1, 22, 43.
Study: NCT00458289
Drug: Lanthanum carbonate (chewed vs. crushed)
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single 1 g oral dose of lanthanum carbonate either chewed or crushed into a fine powder
Study: NCT04501094
Drug: Bintrafusp alfa (M7824)
Normalized name: Darbepoetin Alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1200 mg administered intravenous (IV) every two weeks
Study: NCT00476437
Drug: biphasic insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00476437
Drug: biphasic human insulin
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00401245
Drug: desvenlafaxine succinate sustained release
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titration 100 mg
Study: NCT00401245
Drug: desvenlafaxine succinate sustained release
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titration 50 mg
Study: NCT00401245
Drug: desvenlafaxine succinate sustained release
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titration 25 mg, 50mg
Study: NCT01711827
Drug: Isavuconazole
Normalized name: Isavuconazole
DrugBank: Isavuconazole (DB11633)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01711827
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT00401245
Drug: desvenlafaxine succinate sustained release
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Titration 25 mg
Study: NCT00401245
Drug: desvenlafaxine succinate sustained release
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapering 50 mg, placebo
Study: NCT00401245
Drug: desvenlafaxine succinate sustained release
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapering 50 mg, 25 mg
Study: NCT00401245
Drug: desvenlafaxine succinate sustained release
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapering 50 mg QOD
Study: NCT01230645
Drug: RV568
Normalized name: Ravulizumab
DrugBank: Ravulizumab (DB11580)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RV568 400 ug administered as nasal drops twice daily for 10 days (Day -1 to Day 8)
Study: NCT00230594
Drug: desmopressin
Normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: desmopressin 120 mcg melt tablet; 120 mcg, 240 mcg or 360 mcg administered once daily before bedtime
Study: NCT00891072
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00891072
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03934827
Drug: MRx0518 Capsules
Normalized name: MRx0518
DrugBank: MRx0518 (DB17523)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRx0518 is a live biotherapeutic product consisting of a lyophilised formulation of a proprietary strain of bacterium. The dosing regimen is one capsule orally twice daily for 2-4 weeks until surgery.
Study: NCT03934827
Drug: MRx0518/placebo Capsules
DrugBank: MRx0518 (DB17523)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRx0518/placebo product consist of a lyophilised formulation of either a proprietary strain of bacterium or placebo.The dosing regimen is one capsule orally twice daily for 2-4 weeks until surgery. Placebo capsules are manufactured to mimic MRx0518 capsules and contain the same excipients as the active biotherapeutic product.
Study: NCT02809768
Drug: Avatrombopag
Normalized name: AVATROMBOPAG
DrugBank: Avatrombopag (DB11995)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02809768
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02809768
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02809768
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03361124
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of additional 20 mU Oxytocin
Study: NCT01787110
Drug: Oxygen
Normalized name: Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: see arm description
Study: NCT04920370
Drug: ALXN1720 SC
Normalized name: IMMUNOGLOBULIN, BISPECIFIC, ANTI-(HUMAN SERUM ALBUMIN) (HUMAN-LAMA GLAMA MONOCLONAL ALXN1720 SINGLE-DOMAIN VHH FRAGMENT) FUSION PROTEIN WITH PEPTIDE LINKER (SYNTHETIC 15 AMINO-ACID) FUSION PROTEIN WITH ANTI-(HUMAN COMPLEMENT C5) (HUMAN-LAMA GLAMA MONOCLO
DrugBank: Gefurulimab (DB18928)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALXN1720 will be administered via SC route.
Study: NCT00387517
Drug: Aliskiren/HCTZ
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04920370
Drug: ALXN1720 IV
Normalized name: IMMUNOGLOBULIN, BISPECIFIC, ANTI-(HUMAN SERUM ALBUMIN) (HUMAN-LAMA GLAMA MONOCLONAL ALXN1720 SINGLE-DOMAIN VHH FRAGMENT) FUSION PROTEIN WITH PEPTIDE LINKER (SYNTHETIC 15 AMINO-ACID) FUSION PROTEIN WITH ANTI-(HUMAN COMPLEMENT C5) (HUMAN-LAMA GLAMA MONOCLO
DrugBank: Gefurulimab (DB18928)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALXN1720 will be administered via IV route.
Study: NCT01134341
Drug: Pralatrexate Injection
Normalized name: pralatrexate Injection
DrugBank: Pralatrexate (DB06813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous (IV) push over 30 seconds to 5 minutes via a patent free-flowing IV line containing normal saline (0.9% sodium chloride).~10 or 15 mg/m2, depending on cohort assignment.~Dose reductions allowed for protocol-specified criteria.~Administered weekly for 3 weeks of 4-week cycle (weekly for 3 weeks with one week of rest) until criteria for discontinuation per the protocol are met.
Study: NCT01134341
Drug: Bexarotene Capsules
Normalized name: Bexarotene Capsules
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 150 or 300 mg orally, depending on cohort assignment. Provided as 75 mg capsules and taken with a meal.~Dose reductions allowed for protocol-specified criteria and implemented per the Targretin® package insert.~Administered daily until criteria for study treatment discontinuation per the protocol are met.
Study: NCT01247740
Drug: compounded monobag
Normalized name: BENZOIN COMPOUND
DrugBank: Benzoin (DB14020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: parenteral nutrition
Study: NCT01374620
Drug: Paclitaxel dose escalation
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be administered intravenously over 60 minutes, at D1, D8 and D15, at a given dose.~The Paclitaxel dose (mg/infusion) levels are as follows:~* 40~* 60~* 70~* 75~* 80~* 85~* 90
Study: NCT01374620
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated at the recommended dose in order to confirm the recommended paclitaxel dose in association with metronomic cyclophosphamide
Study: NCT00664287
Drug: niacin (+) laropiprant
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: Patients will receive ER niacin/laropiprant 1 g/20 mg daily. After 4 weeks, ER niacin/laropiprant will be increased to 2 g/40 mg for remainder of study.
Study: NCT00114595
Drug: eicosapentaenoic acid
Normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02333188
Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Normalized name: Albumin-stabilized nanoparticle (130 nm)
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT02333188
Drug: Irinotecan Hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00705315
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel as an IV infusion over 1h at the dose of 75mg/m2 every 3 weeks for 6 cycles
Study: NCT00705315
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin as an IV infusion over 10 min at the dose of 75mg/m2 every 3 weeks for 6 cycles
Study: NCT00705315
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab as an IV infusion over 1h at the dose of 15 mg/kg every 3 weeks for 6 cycles
Study: NCT02809456
Drug: Nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral intake
Study: NCT00784979
Drug: CMVIG
Normalized name: CMVIG
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg/kg IV (60mg/kg/IV/hr initially, titrated up) once a week up to four weeks
Study: NCT02812771
Drug: Efinaconazole
Normalized name: Efinaconazole
DrugBank: Efinaconazole (DB09040)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solution
Study: NCT00864799
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of 3 routes of administration of misoprostol for termination of pregnancy 14-24 weeks
Study: NCT02451306
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See information in arm description.
Study: NCT01959490
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01959490
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01959490
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT01959490
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04500132
Drug: EC-18
Normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EC-18 QD
Study: NCT00683787
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV once every 3 weeks
Study: NCT00683787
Drug: vandetanib
Normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vandetanib once daily
Study: NCT02625506
Drug: Levobupivacaine
Normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine
Study: NCT02625506
Drug: Levobupivacaine and Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine in conjunction with tramadol
Study: NCT01651585
Drug: Valacyclovir arrow
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dosage form:500mg, dosage:8g/day, frequency: 4 a day duration: 23 weeks maximum
Study: NCT01288391
Drug: NNC 0128-0000-2011
Normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 100 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)
Study: NCT01288391
Drug: NNC 0128-0000-2011
Normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 200 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)
Study: NCT02849236
Drug: Ropivacaine (PECS bloc)
Normalized name: Gold-Bloc
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ropivacaine 3.75mg/mL~Injection of a local anesthetic between pectoral major and pectoral minor muscles
Study: NCT02124902
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02124902
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00183196
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone (50 mg/day) plus gabapentin placebo in divided doses for the first 6weeks. Naltrexone (50 mg/day) for rest of 16-weeks
Study: NCT00183196
Drug: Naltrexone plus Gabapentin
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naltrexone (50 mg/day) for 16-weeks plus gabapentin (up to 1200 mg/day in divided doses) for the first 6 weeks
Study: NCT01170507
Drug: vitamin D3 1000 IU orally daily for 5 months
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01170507
Drug: vitamin D3 3000 IU orally daily for 5 months
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01170507
Drug: vitamin D3 5000 IU orally daily for 5 months
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no